Molecular Partners' market value is the price at which a share of Molecular Partners trades on a public exchange. It measures the collective expectations of Molecular Partners AG investors about its performance. Molecular Partners is trading at 2.25 as of the 8th of February 2026. This is a 4.26 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.25. With this module, you can estimate the performance of a buy and hold strategy of Molecular Partners AG and determine expected loss or profit from investing in Molecular Partners over a given investment horizon. Check out Molecular Partners Correlation, Molecular Partners Volatility and Molecular Partners Performance module to complement your research on Molecular Partners.
Understanding that Molecular Partners' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Molecular Partners represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Molecular Partners' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Molecular Partners 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Partners' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Partners.
0.00
11/10/2025
No Change 0.00
0.0
In 2 months and 31 days
02/08/2026
0.00
If you would invest 0.00 in Molecular Partners on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Molecular Partners AG or generate 0.0% return on investment in Molecular Partners over 90 days. Molecular Partners is related to or competes with Innate Pharma, NDT Pharmaceuticals, Brii Biosciences, Scancell Holdings, JW (Cayman), NervGen Pharma, and Ascend Wellness. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and... More
Molecular Partners Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Partners' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Partners AG upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Partners' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Partners' standard deviation. In reality, there are many statistical measures that can use Molecular Partners historical prices to predict the future Molecular Partners' volatility.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Molecular Partners' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Molecular Partners has Sharpe Ratio of -0.12, which conveys that the firm had a -0.12 % return per unit of risk over the last 3 months. Molecular Partners exposes nineteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Molecular Partners' Mean Deviation of 1.58, risk adjusted performance of (0.09), and Standard Deviation of 4.82 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of -0.72, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Molecular Partners are expected to decrease at a much lower rate. During the bear market, Molecular Partners is likely to outperform the market. At this point, Molecular Partners has a negative expected return of -0.61%. Please make sure to verify Molecular Partners' total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if Molecular Partners performance from the past will be repeated at some point in the near future.
Auto-correlation
-0.79
Almost perfect reverse predictability
Molecular Partners AG has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Molecular Partners time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Partners price movement. The serial correlation of -0.79 indicates that around 79.0% of current Molecular Partners price fluctuation can be explain by its past prices.
Additional Information and Resources on Investing in Molecular Pink Sheet
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:
Molecular Partners technical pink sheet analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, pink sheet market cycles, or different charting patterns.
A focus of Molecular Partners technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Molecular Partners trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...